Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10954529 Minimal volume reprogramming of mononuclear cells

Patent 10954529 was granted and assigned to Fate Therapeutics Inc on March, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 10954529 Minimal volume reprogramming of mononuclear cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.